10,000 Matching Annotations
  1. Oct 2026
    1. P9

      Patient9: Female, 9mo at diagnosis, 10mo at ERT

      CasePresentingHPOs:

      HPOsFreeText: classic IOPD, poor response to ERT, Pompe muscle pathology score = 3.7, Glycogen = 43.1 Vv(PAS + /mf)%, larger empty vacuoles = 43.2 Vv (LEV/mf)%, Autophagic vacuoles = 0,31 %/mf

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: homozygous, biopsy taken from  musculus vastus lateralis

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.2431_2432insC

      CAID: CA658795289, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA658795289

      gnomAD: n/a

    2. P3

      Patient3: Female, 2mo at diagnosis, 5mo at ERT

      CasePresentingHPOs:

      HPOsFreeText: classic IOPD, moderate response to ERT, Pompe muscle pathology score = 1.4(a), 3.4(b), Glycogen = 19.5(a), 48.6(b) Vv(PAS + /mf)%, larger empty vacuoles = 10.2(a), 40.1(b) Vv (LEV/mf)%, Autophagic vacuoles = 0,27; 0 %/mf

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: biopsy taken from  musculus vastus lateralis

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: c.1859 G > A this is the variant listed in the paper, but I believe this is a typo as both Clinvar and the allele registry have this position listed as 'C' rather than 'G'

      NM_000152.3:c.1859C>A

      CAID: CA401369666, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1859C%3EA

      gnomAD: n/a

      Variant2: NM_000152.4:c.2481+102_2646+31del (p.Gly828_Asn882del) (exon 18 del)

      ClinVar: 4031, https://www.ncbi.nlm.nih.gov/clinvar/variation/4031/

      gnomAD: n/a

    3. P1

      Patient1: Female, 3mo at diagnosis, 4mo at ERT

      CasePresentingHPOs:

      HPOsFreeText: classic IOPD, moderate response to ERT, Pompe muscle pathology score = 2.2 (a), 3.3(b), Glycogen = 59.4(a), 63.8(b) Vv(PAS + /mf)%, larger empty vacuoles = 6.2(a), 18.3(b) Vv (LEV/mf)%, autophagic vacuoles = 0,25; 0 %/mf

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: biopsy taken from  musculus vastus lateralis

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.104T>C

      CAID: CA401360259, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401360259

      gnomAD: n/a

      Variant2: c.266 C > A This is the variant listed in the paper, but I believe this is a typo as both Clinvar and the allele registry have this position listed as 'G' rather than 'C'

      NM_000152.4(GAA):c.266G>A (p.Arg89His)

      ClinVar: 283219, https://www.ncbi.nlm.nih.gov/clinvar/variation/283219/#summary-evidence

      gnomAD: 7.795e-05, http://exac.broadinstitute.org/variant/17-78078651-G-A

    1. Case2: Female, 68 years report

      HPOsFreeText: 5 years of ERT completed, 6 Minute Walking Test at 275 meters, Forced Vital Capacity at 116%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1629C>G (p.Tyr543Ter)

      CAID: CA401367368 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1629C%3EG

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    2. Case38: Male, 75 years report

      HPOsFreeText: ERT not started, 6 Minute Walking Test at 246 meters

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1560C>G (p.Asn520Lys)

      CAID: CA401367200 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1560C%3EG

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    3. Case34: Male, 46 years report

      HPOsFreeText: ERT not started, 6 Minute Walking Test at 383 meters, Forced Vital Capacity at 73%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1888+1G>A

      CAID: CA8815511 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1888%2B1G%3EA

      gnomAD: European (Non-Finnish) 9.843e-6, Overall 4.375e-6 http://gnomad.broadinstitute.org/variant/17-78086511-G-A


      CaseAddInfo: Late Onset Pompe Disease

    4. Case8: Male, 54 years report

      HPOsFreeText: 8 years of ERT completed, 6 Minute Walking Test at 300 meters, Forced Vital Capacity at 33%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1888+1G>A

      CAID: CA8815511 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1888%2B1G%3EA

      gnomAD: European (Non-Finnish) 9.843e-6, Overall 4.375e-6 http://gnomad.broadinstitute.org/variant/17-78086511-G-A


      CaseAddInfo: Late Onset Pompe Disease

    5. Case14: Female, 69 years report

      HPOsFreeText: 9 years of ERT completed, 6 Minute Walking Test at 200 meters, Forced Vital Capacity at 51%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.118C>T (p.Arg40Ter)

      ClinVar: 426593 https://www.ncbi.nlm.nih.gov/clinvar/variation/426593/

      gnomAD: South Asian 6.561e-5, Overall 1.428e-5 http://gnomad.broadinstitute.org/variant/17-78078503-C-T


      CaseAddInfo: Late Onset Pompe Disease

    6. Case3: Female, 72 years report

      HPOsFreeText: 4 years of ERT completed, 6 Minute Walking Test at 264 meters, Forced Vital Capacity at 56%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.2481+102_2646+31del (p.Gly828_Asn882del) (exon 18 del)

      ClinVar: 4031 https://www.ncbi.nlm.nih.gov/clinvar/variation/4031/

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    7. Case5: Male, 57 years report

      HPOsFreeText: 2 years of ERT completed, 6 Minute Walking Test at 461 meters, Forced Vital Capacity at 49%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.546+1G>T

      CAID: CA401361913 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.546%2B1G%3ET

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    8. Case15: Female, 54 years report

      HPOsFreeText: 8 years of ERT completed, 6 Minute Walking Test at 229 meters, Forced Vital Capacity at 39%

      GenotypingMethod: GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 http://www.ncbi.nlm.nih.gov/clinvar/variation/4027

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1717A>C (p.Asn573His)

      CAID: CA401369056 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1717A%3EC

      gnomAD: Not in gnomAD


      CaseAddInfo: Late Onset Pompe Disease

    1. 13

      Case#: Subject number 13, male, 43 years (diagnosis), 47 years (baseline visit), 45 years (ERT), 44 (ventilation)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness), HP:0002098 (respiratory distress)

      CaseHPOFreeText: mechanical ventilation at Baseline Visit, mechanical ventilation at last visit

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea)

      CaseNotHPOFreeText:

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    2. 21

      Case#: Subject number 21, female, 20 years (diagnosis), 52 years (baseline visit), 45 years (ERT), 39 (age at ventilation)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea), HP:0002098 (respiratory distress)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    3. 8

      Case#: Subject number 8, female, 49 years (diagnosis), 59 years (baseline visit), 52 years (ERT)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea), HP:0002098 (respiratory distress)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    4. 1

      Case#: Subject number 1, female, 38 years (diagnosis), 50 years (baseline visit), 47 years (ERT)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002098 (respiratory distress), HP:0002870 (obstructive sleep apnea)

      CaseNotHPOFreeText: No mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    5. 31

      Case#: Subject number 31, male, 49 years (diagnosis), 51 years (baseline visit)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0002098 (respiratory distress), HP:0001324 (Muscle Weakness)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    6. 10

      Case#: Subject number 10, male, 13 years (diagnosis), 42 years (baseline visit), 39 years (ERT), 38 (ventilation)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness), HP:0002098 (respiratory distress)

      CaseHPOFreeText: mechanical ventilation at Baseline Visit, mechanical ventilation at last visit

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea)

      CaseNotHPOFreeText:

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    7. 19

      Case#: Subject number 19, female, 24 years (diagnosis), 35 years (baseline visit), 29 years (ERT)

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001324 (Muscle Weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0003236 (Elevated circulating creatine kinase concentration), HP:0002870 (obstructive sleep apnea), HP:0002098 (respiratory distress)

      CaseNotHPOFreeText: no mechanical ventilation at Baseline Visit, no mechanical ventilation at last visit

      CasePreviousTesting: "reduced enzymatic activity on fibroblasts, blood leukocytes or skeletal muscle and/or the presence of two known mutations in the GAA gene"

      PreviouslyPublished: N/A

    1. There is a description of 22 Dutch families carrying the c.-32-13T>G mutation, where the course and severity of the disease varied substantially among most of the siblings despite having identical genotypes. This suggests that other components, such as lifestyle, nutrition, environmental influences and other genetic or epigenetic factors, may contribute to explain such clinical inter and intra-familiar variability

      NM_000152.4(GAA):c.-32-13T>G

    2. III-9

      Subject III-9: Female

      CasePresentingHPOs:

      HPOsFreeText: DBS neutral/acid = 36.0

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: asymptomatic, asserted carrier status

      CasePMIDs:

      CasePreviousTesting: DBS

      CaseGenotypingMethod: GAA Genotyping

      Variant: NM_000152.4(GAA):c.2560C>T (p.Arg854Ter)

      ClinVar: 4034, https://www.ncbi.nlm.nih.gov/clinvar/variation/4034/

      gnomAD: 0.0002090, http://gnomad.broadinstitute.org/variant/17-78092070-C-T

    1. 4

      Patient4:

      CasePresentingHPOs:

      HPOsFreeText: Childhood onset Pompe

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting:

      CaseGenotypingMethod: method not described

      Variant1: NM_000152.3:c.1645G>C

      CAID: CA401368767, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401368767

      gnomAD: n/a

      Variant2: NM_000152.3:c.692+1G>C

      CAID: CA8814965, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA8814965

      gnomAD: 0.000004171, https://gnomad.broadinstitute.org/variant/17-78079694-G-C

    2. 7

      Patient7:

      CasePresentingHPOs:

      HPOsFreeText: classic IOPD

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: homozygous

      CasePMIDs:

      CasePreviousTesting:

      CaseGenotypingMethod: method not described

      Variant: NM_000152.4(GAA):c.1124G>T (p.Arg375Leu)

      ClinVar: 283230, https://www.ncbi.nlm.nih.gov/clinvar/variation/283230/

      gnomAD: 0.000008050, https://gnomad.broadinstitute.org/variant/17-78082336-G-T

    1. 1

      Patient1: 40yo

      CasePresentingHPOs:

      HPOsFreeText: HyperCKemia, GAA = 4%, BMI = 25.8, normal CTA, temporo-insular lacunes

      CaseNotHPOs:

      NotHPOsFreeText: no cardiovascular risk factor

      CaseAddInfo: 6yr disease duration

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

    2. 15

      Patient15: 53yo

      CasePresentingHPOs: HP:0002315, HP:0004887, HP:0000822, HP:0003141, HP:0002870, HP:0020038

      HPOsFreeText: hyperCKema, morning headaches, GAA = 13%, BMI = 29.6, right ventricular artery dominant, Normal CT

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: 5yr disease duration, homozygous variants in trans

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

    1. #3

      Case#: Subject number 3, female, 9 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: Family member with PD

      CasePresentingHPOs:

      CaseHPOFreeText: Asymptomatic

      CaseNotHPOs: HP:0002153 (hyperkalemia), HP:0001324 (muscle weakness), HP:0003546 (Exercise intolerance), HP:0001252 (Hypotonia), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0002098 (respiratory distress), HP:0002094 (dyspnoea), HP:0001638 (cardiomyopathy)

      CaseNotHPOFreeText: no biopsy

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.15 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.-32-13T>C

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.1396_1397insG (p.Val466GlyfsTer?)

      Variant 2 ClinVarID: ?

      Variant 2 CAid: CA627699396

      Zygosity: Compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. #16

      Case#: Subject number 16, male, 59 years (report)

      DiseaseAssertion: Pompe disease

      FamilyInfo: No known family member with PD

      CasePresentingHPOs: HP:0002153 (hyperkalemia), HP:0002098 (respiratory distress), HP:0001324 (muscle weakness)

      CaseHPOFreeText:

      CaseNotHPOs: HP:0001252 (Hypotonia), HP:0001638 (cardiomyopathy), HP:0003326 (Myalgia), HP:0002015 (dysphagia), HP:0003546 (Exercise intolerance), HP:0002094 (dyspnoea)

      CaseNotHPOFreeText: no biopsy, not asymptomatic

      CasePreviousTesting: "Enzymatic activity was detected by fluorometric techniques" "The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased."

      glucosidase activity: GAA activity was 0.17 mol/Lh in dried blood spots (normal range >0.75).

      Variant 1: NM_000152.5(GAA):c.-32-13T>C

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.-32-13T>C

      Variant 2 ClinVarID: 4027

      Variant 2 CAid: CA116606

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. 10

      Case#: Patient 10, male, diagnosed 1995 (not given age of diagnosis), age 22 during study period

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None given

      CaseHPOFreeText: None given

      CaseNotHPOs: None given

      CaseNotHPOFreeText: None given

      CasePreviousTesting: None given

      Variant 1: NM_000152.5:c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5:2228A>G

      Variant 2 ClinVarID: 561162

      Variant 2 CAid: CA401324753

      ParentalGenotype: Not provided

    2. 8

      Case#: Patient 8, male, diagnosed 2014 (not given age of diagnosis), age 19 during study period

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None given

      CaseHPOFreeText: None given

      CaseNotHPOs: None given

      CaseNotHPOFreeText: None given

      CasePreviousTesting: None given

      Variant 1: NM_000152.5:c.-32-13T>G (unclear variant nomenclature)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5:c.1548G>A

      Variant 2 ClinVarID: 189025

      Variant 2 CAid: CA274281

      ParentalGenotype: Not provided

    3. 6

      Case#: Patient 6, female, diagnosed 2016 (not given age of diagnosis), age 30 during study period

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None given

      CaseHPOFreeText: Requires wheelchair for long distance movement

      CaseNotHPOs: None given

      CaseNotHPOFreeText: None given

      CasePreviousTesting: None given

      Variant 1: NM_000152.5:c.-32-13T>G (unclear variant nomenclature)

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5:c.525del (unclear variant nomenclature)

      Variant 2 ClinVarID: 4033

      Variant 2 CAid: CA220406

      ParentalGenotype: Not provided

    4. 1

      Case#: Patient 1, male, diagnosed 2000 (not given age), age 62 during study period

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None given

      CaseHPOFreeText: Requires B-pap at night

      CaseNotHPOs: None given

      CaseNotHPOFreeText: None given

      CasePreviousTesting: None given

      Variant 1: NM_000152.5:c.-32-13T>A

      Variant 1 ClinVarID: N/A

      Variant 1 CAid: CA913184742

      Variant 2: NM_000152.5:c.1003G>A

      Variant 2 ClinVarID: 972790

      Variant 2 CAid: CA501005

      ParentalGenotype: Not provided

    1. c.525delT(p.Glu176Argfs*45)

      Case44

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant1: NM_000152.4:c.525delT (p.Glu176Argfs*45)

      ClinVar: 4033 https://www.ncbi.nlm.nih.gov/clinvar/variation/4033/

      gnomAD: European (Non-Finnish) 1.880e-4, Overall 9.959e-5 http://gnomad.broadinstitute.org/variant/17-78078909-CT-C


      Variant2: NM_000152.4:c.1799G>T (p.Arg600Leu)

      CAID: CA401369428 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1799G%3ET

      gnomAD: Not in gnomAD


      CaseAddInfo: Infantile Onset Pompe Disease

    2. [del Exons 15–20]U

      Case26

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant code not given

      Variant1: NM_000152.4: [del Exons 15–20]

      ClinVar: N/A

      gnomAD: N/A


      Variant2: NM_000152.4:c.2012T>G (p.Met671Arg)

      ClinVar: 92469 https://www.ncbi.nlm.nih.gov/clinvar/variation/92469/

      gnomAD: Not in gnomAD


      CaseAddInfo: Infantile Onset Pompe Disease

    3. c.2481+102_2646+31del (p.Gly828_Asn882del)

      Case41

      HPOsFreeText: See Group Phenotypes


      CasePreviousTesting: Sanger sequencing

      CaseMethod1: Sanger sequencing and PCR Amplification

      CaseMethod2: Whole Exome Sequencing (WES)

      CaseGenotypingMethod: Patients were previously confirmed with Pompe disease by Sanger sequencing to capture the pathogenic variants. The process was repeated as part of the study taking care to amplify the coding regions and exon/intron boundaries to compare with the WES results afterwards.


      Variant: NM_000152.4:c.2481+102_2646+31del (p.Gly828_Asn882del) (exon 18 del)

      ClinVar: 4031 https://www.ncbi.nlm.nih.gov/clinvar/variation/4031/

      gnomAD: Not in gnomAD


      CaseAddInfo: Infantile Onset Pompe Disease, Patient is homozygous for this variant

    1. 1

      Case1: Female, 16 years onset, 18 years diagnosis, 38 years report, France

      CasePresentingHPOs: HP:0002540, HP:0002878, HP:0004887 (Inability to walk, Respiratory failure, Respiratory failure requiring assisted ventilation)

      HPOsFreeText: Lost ambulation at 25 years, Started invasive ventilation at 25 years, Started ERT given every other week at a dose of 20 mg/kg at 29 years for 110 months, Peak Anti-rhGAA antibodies at 1:51,200, FVC at 0.43/11 (L / % expected), MIP at 17 (cm H2O), MEP at 19 (cm H2O), Time off ventilation increased from 10 to 40 (min/24 h), Total Motor Function Measure from 38 to 29

      CaseNotHPOs: HP:0030148 (Heart murmur)

      NotHPOsFreeText: No adverse reaction to ERT was recorded

      CaseAddInfo: Late Onset Pompe Disease

    1. PD/Pathogenic-7

      CasePD/Pathogenic-7: 2 weeks diagnosis

      HPOsFreeText: GAA activity 3.0 (nmol · h−1 · mg−1), Mean percentage of normal 4.2%

      GenotypingMethod: Newborn Screening Panels


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.2065G>A (p.Glu689Lys)

      ClinVar: 4030 https://www.ncbi.nlm.nih.gov/clinvar/variation/4030/

      gnomAD: East Asian 0.2355, Overall 0.05524 http://gnomad.broadinstitute.org/variant/17-78087041-G-A


      Variant3: NM_000152.4:c.2167G>A (p.Val723Met)

      CAID: CA8815635 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3:c.2167G%3EA

      gnomAD: East Asian 6.213e-5, Overall 9.462e-6 http://gnomad.broadinstitute.org/variant/17-78087143-G-A


      CaseAddInfo: Patient has one pseudodeficency allele and one pathogenic allele, Nomenclature claims Variant 1 and 2 are in cis

    2. PD/Pathogenic-4

      CasePD/Pathogenic-4: 2 weeks diagnosis

      HPOsFreeText: GAA activity 5.0 (nmol · h−1 · mg−1), Mean percentage of normal 7.0%

      GenotypingMethod: Newborn Screening Panels


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.2065G>A (p.Glu689Lys)

      ClinVar: 4030 https://www.ncbi.nlm.nih.gov/clinvar/variation/4030/

      gnomAD: East Asian 0.2355, Overall 0.05524 http://gnomad.broadinstitute.org/variant/17-78087041-G-A


      Variant3: NM_000152.4:c.752C>T (p.Ser251Leu)

      ClinVar: 325781 https://www.ncbi.nlm.nih.gov/clinvar/variation/325781/

      gnomAD: East Asian 2.760e-3, Overall 3.540e-4 http://gnomad.broadinstitute.org/variant/17-78081415-C-T


      Variant4: NM_000152.4:c.761C>T (p.Ser254Leu)

      ClinVar: 325782 https://www.ncbi.nlm.nih.gov/clinvar/variation/325782/

      gnomAD: East Asian 2.759e-3, Overall 1.947e-4 http://gnomad.broadinstitute.org/variant/17-78081424-C-T


      CaseAddInfo: Patient has one pseudodeficency allele and one pathogenic allele, Nomenclature claims Variant 1 and 2 are in cis, Nomenclature claims Variant 3 and 4 are in cis

    3. PD/Pathogenic-3

      CasePD/Pathogenic-3: 2 weeks diagnosis

      HPOsFreeText: GAA activity 4.9 (nmol · h−1 · mg−1), Mean percentage of normal 6.9%

      GenotypingMethod: Newborn Screening Panels


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.2065G>A (p.Glu689Lys)

      ClinVar: 4030 https://www.ncbi.nlm.nih.gov/clinvar/variation/4030/

      gnomAD: East Asian 0.2355, Overall 0.05524 http://gnomad.broadinstitute.org/variant/17-78087041-G-A


      Variant3: NM_000152.4:c.752C>T (p.Ser251Leu)

      ClinVar: 325781 https://www.ncbi.nlm.nih.gov/clinvar/variation/325781/

      gnomAD: East Asian 2.760e-3, Overall 3.540e-4 http://gnomad.broadinstitute.org/variant/17-78081415-C-T


      Variant4: NM_000152.4:c.761C>T (p.Ser254Leu)

      ClinVar: 325782 https://www.ncbi.nlm.nih.gov/clinvar/variation/325782/

      gnomAD: East Asian 2.759e-3, Overall 1.947e-4 http://gnomad.broadinstitute.org/variant/17-78081424-C-T


      CaseAddInfo: Patient has one pseudodeficency allele and one pathogenic allele, Nomenclature claims Variant 1 and 2 are in cis, Nomenclature claims Variant 3 and 4 are in cis

    1. 1

      Patient1: Male, 0.1mo at ERT start, 33mo at study end

      CasePresentingHPOs:

      HPOsFreeText: treated with 20mg/kg/2wk, patient had 18 infusion associated reactions

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo: homozygous

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1460T>C

      CAID: CA401366851, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401366851

      gnomAD: n/a

    2. 3

      Patient3: Male, 1.2mo at ERT start, 5.5yo at study end

      CasePresentingHPOs:

      HPOsFreeText: treated with 20mg/kg/2wks, patient had 27 infusion associated reactions

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.1933G>T (p.Asp645Tyr)

      ClinVar: 556386, https://www.ncbi.nlm.nih.gov/clinvar/variation/556386/

      gnomAD: 0.000008250, http://gnomad.broadinstitute.org/variant/17-78086719-G-T

      Variant2: NM_000152.4(GAA):c.525delT (p.Glu176Argfs)

      ClinVar: 4033, https://www.ncbi.nlm.nih.gov/clinvar/variation/4033/

      gnomAD: 0.00009959, http://gnomad.broadinstitute.org/variant/17-78078909-CT-C

    1. Ten patients received concomitant immunomodulation (detailed in Supplementary Table S4); six were genotype-predicted as CRIM-negative, three were CRIM-positive, and one lacked genotype data.

      Patient 1

      Variant1: NM_000152.3:c.1654del

      CAID: CA658795262, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA658795262

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.2560C>T (p.Arg854Ter)

      ClinVar: 4034, https://www.ncbi.nlm.nih.gov/clinvar/variation/4034/#clinical-assertions

      gnomAD: 0.0002090, http://gnomad.broadinstitute.org/variant/17-78092070-C-T

    2. Ten patients received concomitant immunomodulation (detailed in Supplementary Table S4); six were genotype-predicted as CRIM-negative, three were CRIM-positive, and one lacked genotype data.

      Patient 2 - homozygous

      Variant: NM_000152.4(GAA):c.2560C>T (p.Arg854Ter)

      ClinVar: 4034, https://www.ncbi.nlm.nih.gov/clinvar/variation/4034/#clinical-assertions

      gnomAD: 0.0002090, http://gnomad.broadinstitute.org/variant/17-78092070-C-T

    1. 6

      Case6: Male, 25 years onset, 56 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 57, GAA Activity at ~10.5 pmol/min/mg before ERT and ~11 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1655T>C (p.Leu552Pro)

      ClinVar: 279811 https://www.ncbi.nlm.nih.gov/clinvar/variation/279811/

      gnomAD: European (Non-Finnish) 7.053e-5, Overall 3.188e-5 http://gnomad.broadinstitute.org/variant/17-78085800-T-C


      CaseAddInfo: Late Onset Pompe Disease

    2. 16

      Case16: Female, 37 years onset, 49 years diagnosis, Italy

      HPOsFreeText: See Group Phenotypes, ERT started at 50, GAA Activity at ~4 pmol/min/mg before ERT and ~11 after

      GroupGenotypingMethod: PCR Amplification and GAA Gene Sequencing


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 http://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Variant2: NM_000152.4:c.1465G>A (p.Asp489Asn)

      ClinVar: 92465 https://www.ncbi.nlm.nih.gov/clinvar/variation/92465/

      gnomAD: European (Finnish) 4.621e-5, Overall 1.195e-5 http://gnomad.broadinstitute.org/variant/17-78084553-G-A


      CaseAddInfo: Late Onset Pompe Disease

    1. Detailed characteristics of these patients

      Patient3: female, 62yo, adult onset

      CasePresentingHPOs:

      HPOsFreeText: LOPD, BMI = 19.4;19.7, WGMS = 3;3

      CaseNotHPOs: HP:0002355

      NotHPOsFreeText: did not require respiratory support

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant2: c.2322_2323ins no ClinVar, no CAID

    2. Detailed characteristics of these patients

      Patient8: female, 51yo, adult onset

      CasePresentingHPOs:

      HPOsFreeText: LOPD, BMI = 26.6 / 27.2 / n-a, required use of wheelchair, WGMS = 4 / 4 / n-a

      CaseNotHPOs:

      NotHPOsFreeText: did not require respiratory support

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.4(GAA):c.-32-13T>G

      Clinvar: 4027, https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: 0.003582, http://exac.broadinstitute.org/variant/17-78078341-T-G

      Variant2: NM_000152.4(GAA):c.877G>A (p.Gly293Arg)

      ClinVar: 4036, https://www.ncbi.nlm.nih.gov/clinvar/variation/4036/

      gnomAD: 0.00001807, http://gnomad.broadinstitute.org/variant/17-78081617-G-A

    1. 3.1 Description of the study population

      Patient10: IOPD Group, 46days old

      CasePresentingHPOs:

      HPOsFreeText: LDH = 425 U/L, CK = 221 U/L, ALT = 41 U/L, AST = 61 U/L, Mann-Whitney Test = 2

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.1935C>A (p.Asp645Glu)

      ClinVar: 4029, https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: 0.0001240, https://gnomad.broadinstitute.org/variant/17-78086721-C-A

    2. 3.1 Description of the study population

      Patient7: IOPD Group, 10days old

      CasePresentingHPOs:

      HPOsFreeText: LDH = 431 U/L, CK = 237 U/L, ALT = 23 U/L, AST = 58 U/L, Mann-Whitney Test = 2

      CaseNotHPOs:

      NotHPOsFreeText:

      CaseAddInfo:

      CasePMIDs:

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.1935C>A (p.Asp645Glu)

      ClinVar: 4029, https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: 0.0001240, https://gnomad.broadinstitute.org/variant/17-78086721-C-A

    1. 3

      Patient3: Female

      CasePresentingHPOs: HP:0002194, HP:0001522

      HPOsFreeText: ERT dosage = 20 mg/kg/2 w, CRIM negative

      CaseNotHPOs: HP:0004887

      NotHPOsFreeText:

      CaseAddInfo: Symptom onset at 3d, diagnosis at 1mo, ERT at 2mo, ERT lasted for 1mo, died at 3mo.

      CasePMIDs: 22252923, 27629047

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1657C>T

      CAID: CA401368835, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1657C%3ET

      gnomAD: n/a

    2. 12

      Patient12: Female

      CasePresentingHPOs: HP:0002194, HP:0001522

      HPOsFreeText: ERT dosage = 20mg/kg/2w, CRIM negative

      CaseNotHPOs: HP:0004887

      NotHPOsFreeText:

      CaseAddInfo: Symptom onset at 4mo, diagnosis at 6mo, ERT at 8mo, ERT lasted for 0.5mo, died at 8.5mo

      CasePMIDs: 22252923, 27629047

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.3:c.1657C>T

      CAID: CA401368835, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.1657C%3ET

      gnomAD: n/a

    1. 10/M

      Patient10: male

      CasePresentingHPOs: HP:0011471, HP:0001270, HP:0004887, HP:0002546, HP:0001371

      HPOsFreeText: CRIM negative, Anti-rh GGA antibodies maximum titer = 1:25.600, immunomodulation = 14m, infusion associated reaction, tracheostomy, partial heart normalization

      CaseNotHPOs:

      CaseAddInfo: variants 1-3 in cis, but homozygous in trans, symptom onset at 2yo, diagnosis and ERT at 7yo. Died at 60mo due to cardiorespiratory failure.

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.1833_1839del

      CAID: CA913184757, http://reg.clinicalgenome.org/redmine/projects/registry/gene_indel

      gnomAD: n/a

      Variant2: NM_000152.3:c.1846G>T

      CAID: CA401369607, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401369607

      gnomAD: n/a

      Variant3: NM_000152.3:c.1847_1848insT

      CAID: CA913184758, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA913184758

      gnomAD: n/a

    2. 20/F

      Patient20: Female

      CasePresentingHPOs: HP:0004887, HP:0011471, HP:0001270, HP:0002546, HP:0000365

      HPOsFreeText: CRIM positive, Anti-rh GGA antibodies maximum titer = 1:1.600, tracheostomy, partial heart normalization, moderate periventricular white matter abnormalities (hypomyelination)

      CaseNotHPOs: HP:0002421, HP:0001371

      NotHPOsFreeText: infusion associated reaction

      CaseAddInfo: homozygous variant in trans, symtom onset and diagnosis at 4yo, ERT at 5yo

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant: NM_000152.4(GAA):c.1564C>G (p.Pro522Ala)

      ClinVar: 371277, https://www.ncbi.nlm.nih.gov/clinvar/variation/371277/

      gnomAD: n/a

    3. 6/F

      Patient6: female

      CasePresentingHPOs: HP:0001270

      HPOsFreeText: CRIM positive, partial heat normalization

      CaseNotHPOs: HP:0004887, HP:0025156, HP:0001371

      NotHPOsFreeText: infusion associated reaction

      CaseAddInfo: variants in trans, symptom onset at 4yo, diagnosis at 6yo, ERT at 10yo. Died due to infusion reaction with ERT.

      CasePreviousTesting: same as group

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3(GAA):c.742delC

      CAID: CA658795236, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.3%3Ac.742delC

      gnomAD: n/a

      Variant2: NM_000152.4(GAA):c.896T>C (p.Leu299Pro)

      ClinVar: 180144, https://www.ncbi.nlm.nih.gov/clinvar/variation/180144/

      gnomAD: n/a

    1. girl

      CaseD: Female, 9 months onset, 12 months diagnosis

      CasePresentingHPOs: HP:0001270, HP:0003324 (Motor delay, Generalized weakness)

      HPOsFreeText: CRIM positive, Requires non-invasive ventilation during nighttime

      CaseNotHPOs: HP:0100543, HP:0002540, HP:0001638 (Cognitive impairment, Inability to walk, Cardiomyopathy)

      CaseAddInfo: Infantile-Onset Pompe Disease

    1. CaseIP2-5: Male, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 0.13 umol/hr/L, Serum CK at 443 U/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.1396G>T (p.Val466Phe)

      CAID: CA401366509 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1396G%3ET

      gnomAD: Not in gnomAD


      Variant2: NM_000152.4:c.1935C>A (p.Asp645Glu)

      ClinVar: 4029 https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: East Asian 1.729e-3, Overall 1.240e-4 http://gnomad.broadinstitute.org/variant/17-78086721-C-A


      CaseAddInfo: Infantile Onset Pompe Disease

    2. CaseOPOPD-51: Male, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 1.03 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.1822C>T (p.Arg608Ter)

      CAID: CA8815488 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1822C%3ET

      gnomAD: East Asian 5.103e-5, Overall 1.806e-5 http://gnomad.broadinstitute.org/variant/17-78086444-C-T


      CaseAddInfo: One Pompe Mutation allele and One Pseudodeficency Mutation allele

    3. CaseOPTPD-4: Male, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 0.72 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.752C>T (p.Ser251Leu)

      ClinVar: 325781 https://www.ncbi.nlm.nih.gov/clinvar/variation/325781/

      gnomAD: East Asian 2.760e-3, Overall 3.540e-4 http://gnomad.broadinstitute.org/variant/17-78081415-C-T


      Variant3: NM_000152.4:c.761C>T (p.Ser254Leu)

      ClinVar: 325782 https://www.ncbi.nlm.nih.gov/clinvar/variation/325782/

      gnomAD: East Asian 2.759e-3, Overall 1.947e-4 http://gnomad.broadinstitute.org/variant/17-78081424-C-T


      CaseAddInfo: One Pompe Mutation allele and Two Pseudodeficency Mutation alleles, Nomenclature indicates patient is homozygous for Variant 1 and Variants 2 and 3 are in cis with each other and only one copy of 1

    4. CaseIP-3: Female, Taiwan, Birth diagnosis

      HPOsFreeText: 4MU enzyme activity at 0.42, MS/MS ennzyme activity at 0.10

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.1935C>A (p.Asp645Glu)

      ClinVar: 4029 https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: East Asian 1.729e-3, Overall 1.240e-4 http://gnomad.broadinstitute.org/variant/17-78086721-C-A


      CaseAddInfo: Infantile Onset Pompe Disease, Nomenclature indicates Variant 1 and 2 are in cis and that the patient is homozygous for this allele

    5. CaseOPOPD-48: Female, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 1.02 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.1508_1510del (p.Val503del)

      CAID: CA627699576 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvs=NM_000152.4%3Ac.1508_1510del

      gnomAD: East Asian 5.438e-5, Overall 3.980e-6 http://gnomad.broadinstitute.org/variant/17-78084592-ATGG-A


      Variant2: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      CaseAddInfo: One Pompe Mutation allele and One Pseudodeficency Mutation allele, 1 other has the same genotype

    6. CaseOPOPD-53: Female, Taiwan, Birth diagnosis

      HPOsFreeText: GAA (MS/MS) enzyme activity at 0.80 umol/hr/L

      GenotypingMethod: GAA Gene Sequencing and PCR Amplification


      Variant1: NM_000152.4:c.1726G>A (p.Gly576Ser)

      ClinVar: 92467 https://www.ncbi.nlm.nih.gov/clinvar/variation/92467/

      gnomAD: East Asian 0.1427, Overall 0.01700 http://gnomad.broadinstitute.org/variant/17-78085871-G-A


      Variant2: NM_000152.4:c.1935C>A (p.Asp645Glu)

      ClinVar: 4029 https://www.ncbi.nlm.nih.gov/clinvar/variation/4029/

      gnomAD: East Asian 1.729e-3, Overall 1.240e-4 http://gnomad.broadinstitute.org/variant/17-78086721-C-A


      CaseAddInfo: One Pompe Mutation allele and One Pseudodeficency Mutation allele, 3 other people have this genotype

    1. 5

      Case#: Patient 5, Female, 3.0 months old at diagnosis, African American

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0032988, HP:0001638

      (Persistent head lag, Cardiomyopathy)

      CaseHPOFreeText:

      Previous to ERT patient was invasively ventilated, patient was unable to sit or roll over. NJ feeds started at age 3 months

      Currently patient requires Oxygen and BiPAP at night. Stands with support and uses G tube for feeding.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: No GAA measurement

      Variant: NM_000152.5(GAA):c.2560C>T (p.Arg854Ter)

      ClinVar: 4034

      CAID: CA340130

      gnomAD: Highest population MAF= 0.001891 (African)

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. 17

      Patient17: Male, Caucasian

      CasePresentingHPOs: HP:0003678, HP:0002093, HP:0003325, HP:0003701, HP:0003388, HP:0002111, HP:0003458

      HPOsFreeText: normal CK levels, back muscle weakness, variability in muscle fibre diameter and glycogen accumulation. Slightly reduced alpha-glucosidase activity. Treated with ERT.

      CaseNotHPOs: HP:0003236

      CaseAddInfo: onset as a young adult, Pompe confirmed via Sanger Sequencing and DBS results.

      CasePreviousTesting: same as group, EMG, muscle biopsy

      CaseGenotypingMethod: same as group

      Variant1: NM_000152.3:c.1192delC

      CAID: CA628018372, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA628018372

      gnomAD: n/a

      Variant2: NM_000152.3:c.2716G>A

      CAID: CA401326980, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401326980

      gnomAD: n/a

    1. 6

      Case#: P 6, Male, 2.8 months when started ERT (Died at 18.2 months old), ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001639 , HP:0001252 , HP:0003701, HP:0002090

      (Hypertrophic cardiomyopathy, Muscular hypotonia, Proximal muscle weakness, Pneumonia)

      CaseHPOFreeText: Pneumonia with deterioration was a complication during ERT. Also patient suffered progressive hypertrophic cardiomyopathy.

      AR IV

      Required ventilation

      Best motor status was being able to sit

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Patient did not required tube feeding

      CasePreviousTesting: CRIM status was unknown

      Antibody titer was 1:84,000

      Variant: NM_000152.5(GAA):c.915G>A (p.Gly305=)

      ClinVar: 188478

      CAID: CA198779

      gnomAD: N/A

      ParentalGenotype: Bothe the maternal an paternal allele of the GAA gene carried the variant c.915G>A (p.Gly305=)

      PreviouslyPublished: N/A

    1. 7

      Case#: Subject number 7(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 283 U/L (30-135 U/L is normal), Hex4: 2.6 mmol/mol Creatinine (≤3.0 mmol/mol Creatinine is normal)

      glucosidase activity: GAA activity #1 was 1.05 micromole/L/h and GAA activity #2 (NBS) 0.19 in dried blood spots (>2.10 micromole/L/h is normal). 2.2 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      Variant 1 ClinVarID: 4027

      Variant 1 CAid: CA116606

      Variant 2: NM_000152.5(GAA):c.546 G>A

      Variant 2 ClinVarID: 280955

      Variant 2 CAid: CA8814895

      Zygosity: compound heterozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    2. 23

      Case#: Subject number 23(L)

      DiseaseAssertion: Late Onset Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: CK testing: 48 U/L (60-305 U/L is normal), AST: 73 U/L (22-71 U/L is normal), ALT: 28 U/L (7-50 U/L is normal), BNP 102.3 pg/mL (0.0–100.0 pg/mL is normal)

      glucosidase activity: GAA activity #1 was 1.12 micromole/L/h and GAA activity #2 (NBS) 0.62 in dried blood spots (>2.10 micromole/L/h is normal). 2.5 in confirmatory testing (>3.88 is normal).

      Variant 1: NM_000152.5(GAA):c.2238G>C

      Variant 1 ClinVarID: 265160

      Variant 1 CAid: CA8815665

      Variant 2: NM_000152.5(GAA):c.2238G>C

      Variant 2 ClinVarID: 265160

      Variant 2 CAid: CA8815665

      Variant 3: NM_000152.5(GAA):c.2065G>A

      Variant 3 ClinVarID: 4030

      Variant 3 CAid: CA116612

      Zygosity: homozygous

      ParentalGenotype: N/A

      PreviouslyPublished: N/A

    1. 8

      Case#: Patient 8, Gender N/A, Onset at 1-2 months. Death at 13 months. Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0002240, HP:0001252, HP:0002789, HP:0001698 (Hepatomegaly, Muscular hypotonia, Tachypnea, Pericardial effusion)

      CaseHPOFreeText: Hepatomegaly is mild, Pericardial effusion is mild, BHV, SDD

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Normal PR Interval

      CasePreviousTesting: GAA activity in leukocytes was 1.46% of normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant: NM_000152.5(GAA):c.877G>A (p.Gly293Arg)

      ClinVar: 4036

      CAID: CA116622

      gnomAD: Highest population MAF = 0.00005704 (Latino)

      ParentalGenotype: Both parents were carriers of the variant c.877G>A (p.Gly293Arg)

      PreviouslyPublished: N/A

    2. 3

      Case#: Patient 3, Gender N/A, 5-6 months old when diagnosed.13 months when died, Southeast Asian

      DiseaseAssertion: Pompe disease

      FamilyInfo:

      CasePresentingHPOs: HP:0002094 HP:0001639. HP:0005165 (Hypertrophic Cardiomyopathy, Dyspnea, Shortened PR interval)

      CaseHPOFreeText: Generalized Muscle weakness

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: GAA enzyme activity in leukocytes was 0% of the normal control value.

      PCR of all exons was performed and subsequently subjected to capillary Sanger sequencing in both directions

      Variant1: NM_000152.5(GAA):c.1099T>C (p.Trp367Arg)

      ClinVar:<br /> 555820

      CAID: CA401364951

      gnomAD: N/A

      Variant2: NM_000152.5(GAA):c.1942G>A (p.Gly648Ser)

      ClinVar: 188902

      CAID: CA274102

      gnomAD: Highest population MAF = 0.0003365 (South Asian)

      ParentalGenotype: Father was carrier for Variant1 NM_000152.5(GAA):c.1099T>C (p.Trp367Arg)

      Mother was carrier of Variant 2 NM_000152.5(GAA):c.1942G>A (p.Gly648Ser)

      PreviouslyPublished: N/A

    1. 1

      Case#: Patient 1

      DiseaseAssertion: Pompe Disease

      FamilyInfo: None given

      CasePresentingHPOs: None

      CaseHPOFreeText: None

      CaseNotHPOs: None

      CaseNotHPOFreeText: None

      CasePreviousTesting: Single gene sequencing with Ion Torrent Persional Genome Machine

      Glucosidase activity: 0.0 nmol 5MU/hr/mL

      Variant 1: NM_000152.5:c.2065G>A

      Variant 1 ClinVarID: 4030

      Variant 1 CAid: CA116612

      Variant 2: NM_000152.5:c.1726G>A

      Variant 2 ClinVarID: 92467

      Variant 2 CAid: CA145760

      Variant 2: NM_000152.5:c.596A>G

      Variant 3 ClinVarID: 92486

      Variant 3 CAid: CA145785

      Variant 2: NM_000152.5:c.668G>A

      Variant 4 ClinVarID: 92488

      Variant 4 CAid: CA145791

      ParentalGenotype: Not provided

    1. P6

      Case#: Subject number 6, male, 4 months (onset), 4 months (first admission)

      DiseaseAssertion: Pompe disease

      FamilyInfo: "no family history of neuromuscular disorders"

      CasePresentingHPOs: HP:0004887 (respiratory failure requiring assisted ventilation), HP:0001639 (hypertrophic cardiomyopathy), HP:0001522 (death in infancy), HP:0002090 (pneumonia)

      CaseHPOFreeText: infantile-onset, dysphagia at baseline

      CaseNotHPOs:

      CaseNotHPOFreeText: no tracheostomy, not on BiPAP

      CasePreviousTesting: “GAA activity in peripheral blood leukocytes lower than normal”; on enzyme replacement therapy

    1. 5a

      Family 5 - Patients 5a and 5b

      FamilyPresentingHPOs: HP:0009027, HP:0000467, HP:0003327, HP:0003691, HP:0002650, HP:0040081, HP:0100284

      HPOsFreeText: Myotonic discharges in paraspinal, tibialis anterior, first dorsal interosseous, and biceps muscles, Myopathic muscle unit action potentials, 5b muscular pathology with Severe lysosomal vacuolar myopathy with prominent glycogen excess

      FamilyNotHPOs: HP:0010628, HP:0002015, HP:0003306

      Ethnicity: Iranian

      ProbandLabel: 5a, male, 10yo at onset, 12yo at diagnosis

      FamilyAddInfo: 5b (female) dx at 15 yo, 5a MRC sum score = 94, 5b MRC sum score = 91

      FamilyPreviousTesting: Respiratory Evaluation: 5a FVC = 91%, 5b FVC = 106%, 5a CK = 1,202 U/L, 5b CK = 907 U/L, muscle pathology (examined only in 5b), DBS enzyme activity (with inhibition) for 5a = 0.5 μmol/L/h, for 5b = 0.6 μmol/L/h, NCS, EMG

      FamilyGenotypingMethod: GAA analyzed with Sanger Sequencing for entire coding region and conserved exon-intron splice junctions, PCR performed for deletion screening

      Variant: NM_000152.3:c.1837T>G

      ClinVar: n/a

      CAID: CA401369569, http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA401369569

      gnomAD: n/a

    1. 10 mg/kg (N = 3)

      Case5HPOsFreeText: 10 mg/kg GAA treatment, GAA activity at 0.6 pmol/punch/hr, GAA activity at 6% lower limit of normal

      CaseAddInfo: Late Onset Pompe Disease


      CaseGenotypingMethod: Method not described, only that the diagnosis was "confirmed … based on 2 GAA gene mutations"


      Variant1: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 https://gnomad.broadinstitute.org/variant/17-78078341-T-G


      Unknown variant, likely a typo

      Variant2: NM_000152.4:c.193G>T

      ClinVar:

      gnomAD:


      CaseAddInfo:

    2. 20 mg/kg (N = 16)

      Case9HPOsFreeText: 20 mg/kg GAA treatment, GAA activity at 0.6 pmol/punch/hr, GAA activity at 5.5% lower limit of normal

      CaseAddInfo: Late Onset Pompe Disease


      CaseGenotypingMethod: Method not described, only that the diagnosis was "confirmed … based on 2 GAA gene mutations"


      Variant: NM_000152.4:c.-32-13T>G

      ClinVar: 4027 https://www.ncbi.nlm.nih.gov/clinvar/variation/4027/

      gnomAD: Ashkenazi Jewish 5.541e-3, Overall 3.401e-3 https://gnomad.broadinstitute.org/variant/17-78078341-T-G


      CaseAddInfo: Patient is homozygous for this variant

    1. 4

      Case#: Patient 4, Gender unknown, age unknown, ethnicity unknown

      DiseaseAssertion: Pompe disease

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0001638, HP:0003756

      (Cardiomyopathy, Skeletal myopathy)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: Sequence analysis of the GAA gene was performed in a CLIA and CAP certified laboratory. Cross Reactive Immune reaction was indeterminate in peripheral blood mononuclear cells (PBMCs)

      Cross Reactive Immune reaction was not available in Dried blood spots.

      Variant: NM_000152.5(GAA):c.2560C>T (p.Arg854Ter)

      ClinVar: 4034

      CAID:CA340130

      gnomAD: Highest population MAF= 0.001891 (African)

      ParentalGenotype: N/A

    1. PATIENT 2

      Case#: Patient 2, Male, 71 year old, ethnicity unknown

      DiseaseAssertion: Pompe disease

      diagnosed at age 52 with SMA type III following an EMG reporting neurogenic changes and a muscle biopsy from a hamstring muscle that demonstrated denervation atrophy

      FamilyInfo: N/A

      CasePresentingHPOs: HP:0003701, HP:0003445

      (Proximal muscle weakness, EMG:neuropathic changes

      CaseHPOFreeText: Normal strength in the upper extremities with moderate weakness of hip flexion at 3/5, hip abduction 3–4/5, hip adduction 3–4/5, and hamstrings 4/5.

      EMG showed myotonic discharges in the anterior tibialis, medial gastrocnemius, iliopsoas, tensor fasciae latae, and biceps brachii muscles.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      Staining for PAS and acid phosphatase was normal.

      Serum CK was 208 U/L (normal range 70–185)

      CasePreviousTesting: GAA activity was 1.3pmol/punch/h (normal 10–49 pmol/punch/h) and he was found to have 2 heterozygous mutations

      Variant 1: NM_000152.5(GAA):c.-32-13T>G

      ClinVar: 4027

      CAID: CA116606

      gnomAD: Highest population MAF= 0.005541 (Ashkenazi Jewish)

      Variant 2: NM_000152.5(GAA):c.1841C>A (p.Thr614Lys)

      ClinVar: 167113

      CAID: CA234050

      gnomAD: Highest population MAF= 0.00004784 (European nin-Finnish)

      ParentalGenotype:N/A

      PreviouslyPublished:N/A

    1. In 1986, a preliminary report described a girl

      Case1: Female, 22 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 1

      ParentalGenotype: The patient's parents revealed reduced concentrations of glycoprotein llb-Illa and were considered to be heterozygotes. See Fig 1

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000132, HP:0000978

      (Severe epistaxis, gingival bleeding, menorrhagia, spontaneous bruising)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: Platelets had much reduced alphaIIb3 when estimated by crossed immunoelectrophoresis

      PlateletAggregation: Platelet aggregation was absent with ADP, arachidonic acid, and collagen.

      CasePreviousTesting: Sequenced all exons and splice sites of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1073G>A (p.Arg358His) and NM_000419.3:c.1234G>A (p.Gly412Arg)

      LegacyVariant: (p.Arg327His) and (p.Gly381Arg)

      ClinVar: 2896 and 381748

      CAiD: CA115839 and CA8603182

      gnomAD: MAF in the Latino population is 0.0001453 https://gnomad.broadinstitute.org/variant/17-42458406-C-T

      PreviouslyPublished: PMID: 3762006 proband is mentioned in this article

    1. M2

      Case2: Patient M2, Female, French Gypsy, age is not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Figure 2 for pedigree

      ParentalGenotype: Unaffected parents see pedigree Fig 2

      CasePresentingHPOs: N/A

      CaseHPOFreeText: France, GT is particularly frequent in the Gypsy population, mainly represented by the Manouche tribe. Their clinical phenotype is the same as for classic type I disease, with a moderate and occasional severe bleeding syndrome

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis has shown that these patients' surface expresses <5% of normal GPIIIa and GPIIb levels (we are not given an exact value for each proband)

      PlateletAggregation: "Absent platelet aggregation" this is all the information we are given for platelet aggregation

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD: N/A

    1. EFFECTS OF TICLOPIDINE ON MONOCLONAL ANTI-CD9 ANTIBODY-INDUCED PLATELET AGGREGATION AND MICROPARTICLE GENERATIO

      PMID: 1604445

      Gene: ITGA2B and ITGB3

      HGNC: 6138 and 6156, respectively as shown above

      NoEvidence: This article does not mention Glanzmann thrombasthenia probands with variants in ITGA2B and/or ITGB3; therefore, there is no evidence. In this study, they analyzed the effects of ticloplidine on anti-CD9 antibody-induced platelet aggregation as well as on the release of microparticles by platelets exposed to the antibodies in vitro.

    1. RS

      Case37: Patient RS

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0000132

      (Epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.1260G>A and the other variant won't show up in CAR

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623200

      gnomAD: MAF in the African population is 0.00004005 https://gnomad.broadinstitute.org/variant/17-45368454-G-A

      PreviouslyPublished: Reference 60

    2. Family I

      Case23: Family I from GT database, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.262C>T (p.Arg88Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400020703

      gnomAD: MAF in the Other population 0.0001385 https://gnomad.broadinstitute.org/variant/17-45360816-C-T

      PreviouslyPublished: Reference number 28

    3. Substitution41KWIHomozygoteIVS1

      Case1: Patient KW (this patient can be found in the GT database)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225

      (Epistaxis, gingival bleeding)

      CaseHPOFreeText: Blood transfusions needed

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Surface expression of GPIIb/GPIIIa not reported for this patient

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: 4.5-KB DEL, EX2-9

      LegacyVariant: N/A

      ClinVar: 2890

      CAiD: N/A

      gnomAD: N/A

      PreviouslyPublished: PMID: 1702098

    1. Supplementary Table S1:

      Case40: GT47, French, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.832del (p.Asp278IlefsTer101)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940374

      gnomAD: N/A

    2. Supplementary Table S1:

      Case34: GT40, Canadian/Pakistani, gender and age not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients had a life-long history of mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients in this study met the clinical and platelet function requirements for GT-- this includes an absent or strongly reduced expression of alphaIIbBeta3 in platelets

      PlateletAggregation: All patients in this study met the clinical and platelet function requirements for GT-- this includes absent or severely reduced platelet aggregation with at least three physiological agonists

      CasePreviousTesting: Sanger sequencing was performed. Sanger sequencing ensured coverage of all exons and splice sties of the ITGA2B and ITGB3 genes and extended 300-500 bp into the introns as well as including the UTR. They sequenced 416 bp upstream of the ITGA2B promoter and 463 bp upstream of the ITGB3 promoter. In total they sequenced 51.2% of the ITGA2B gene and 19.4% of the larger ITGB3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.857T>A (p.Val286Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805011

      gnomAD: N/A

    1. A new variant of Glanzmann's thrombasthenia with defective activation-dependent fibrinogen binding and altered expression of epitopes for several monoclonal antibodies against GP IIb-IIIa

      PMID: 21043690

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions a GT patient LB with GT; however, no specific variants in ITGA2B and/or ITGB3 are mentioned in this patient therefore there is insufficient evidence

    1. The patient

      Case1: Female, 5 years old, Swiss (from Morocco)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother

      ParentalGenotype: Mother and father are heterozygous for the variant of interest

      CasePresentingHPOs: HP:0001250, HP:0001270, HP:0000967, HP:0001892

      (Seizures, retarded motor development, petechia, hemorrhagic diathesis)

      CaseHPOFreeText: Subepndymal hematomas, cortical tubera, hydrocephalus internus

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry protein expression results can be seen in Figure 1

      PlateletAggregation: Platelets failed to aggregate with ADP, collagen, or arachidonic acid; however, ristocetin induced platelet agglutination was normal

      CasePreviousTesting: Amplified DNA fragments containing exon 11 of the GPIIIa gene were purified by PCR preps DNA purification resin and wizard.

      Gene: ITGB3

      Variant: NM_000212.2:c.1702T>C (p.Cys568Arg)

      LegacyVariant: (p.Cys542Arg)

      ClinVar: N/A

      CAiD: CA400032350

      gnomAD: N/A

    1. Evaluation of platelet surface glycoproteins in patients with Glanzmann thrombasthenia: Association with bleeding symptoms

      PMID: 28948953

      Gene: ITGA2B and ITGB3

      HGNC: 6138 and 6156

      NoEvidence: There are no probands with specific variants-- rather, in this article, 51 patients of Glaznmann thrombasthenia were diagnosed by platelet aggregation studies and were evaluated for the expression of CD41, CD61, CD42a and CD42b on platelet surface by flow cytometry. The association between the clinical phenotype based on bleeding score and GT subtype on flow cytometric evaluation was assessed.

    1. brother (3years younger) was quickly shown also to have both GT and MTP (Figure1A) with epistaxis the main cause of his bleedin

      Case2:

      DiseaseAssertion: Glanzmann Thrombesthenia and Macrothrombocytopenia (MTP)

      FamilyInfo: Case1 (his older sister) and no parental information.

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0011877

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: No information for the brother on protein expression.

      CasePreviousTesting: As a part of an initial testing of this patient's gene panel (not specified which genes), DNA from this patient was submitted to ThromboGenetics in Cambridge UK. While confirming the two ITGB3 mutations described, an additional finding was a heterozygous mutation in TUBB1.

      Gene: ITGB3

      Variant: NM_000212.2:c.565C>T and NM_000212.2:c.629G>C

      LegacyVariant: N/A

      ClinVar: 2890

      CAiD: CA291224669 and CA400023389, respectively as written in variant section.

      gnomAD: Maximum allele frequency for the variant NM_000212.2:c.565C>T: 0.00002638 https://gnomad.broadinstitute.org/variant/17-45362012-C-T

    1. Sibling allogeneic bone marrow transplantationin a patient with type I Glanzmann’s thrombasthenia

      PMID: 9359503

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This mentions a Glanzmann thrombasthenia patient; however, no variants in ITGA2B and/or ITGB3 are mentioned in this patient; therefore, we have insufficient evidence

    1. GT38

      Case24: (GT38) Gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2338del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940686

      gnomAD N/A

    2. GT23

      Case33: (GT23) Gender, age and ethnicity are not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Both brothers are heterozygous for this mutation and sister is normal

      ParentalGenotype: Father is heterozygous for the NM_000419.3:c.800-2A>T mutation and mother does not harbor this mutation. Mother is heterozygous for the NM_000419.3:c.1210+4A>G mutation and father does not have this mutation.

      CasePresentingHPOs:

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NM_000419.3:c.800-2A>T and NM_000419.3:c.1210+4A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805150 and CA915940692

      gnomAD N/A

    3. 34

      Case5: (GT34), Gender, age and ethnicity not reported

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Inclusion criteria were patients with a history of mucocutaneous bleeding (Figure 1 shows a bar diagram of all the clinical manifestations in the patient cohort in this article)

      CaseNotHPOs: N/A

      ProteinExpression: Platelet receptor alphaIIbbeta3 protein was analyzed by flow cytometry followed by western blotting

      Platelet Aggregation: Inclusion criteria for probands was absent or reduced platelet aggregation with agonists such as ADP, adrenaline, arachidonic acid, and collagen (no mention of ristocetin here-- this article does not tell us the specific aggregation for each proband in the paper)

      CasePreviousTesting: For mutation analysis of ITGA2B and ITGB3 genes, DNA extraction from whole blood, PCR, heteroduplex PCR followed by CSGE and DNA sequencing were performed. All 30 exons of ITGA2B and 15 exons of ITGB3, as well as their promoters, were analyzed by CSGE following heteroduplex PCR.

      Gene: ITGA2B

      Variant: NC_000017.11:g.44393555C>T (g.951G>A promoter variant)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913189168

      gnomAD N/A

    1. TG

      Case13: Patient TG, gender, age and ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type I

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who had minor symptoms, such as epistaxis or gum bleeds, and moderate bleeders suffered, in addition, from bleeding complications after surgery and trauma. Severe bleeders were defined as those with a history of spontaneous or life-threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusion. See Table 1.

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 6

      PlateletAggregation: See Table 6

      CasePreviousTesting: To ascertain the mutations, we sequenced the coding regions of the αIIb and β3 subunits including the exon/intron boundaries

      Gene: ITGA2B

      Variant: NM_000419.3:c.3060G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA500261104

      gnomAD: N/A

    1. G

      Case7: Patient ID G, Female, 1 year old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A (Table 1 does mention family history of bleeding)

      ParentalGenotype: N/A (Parents are consangenous)

      CasePresentingHPOs: HP:0000978, HP:0004406, HP:0000225)

      (Easy bruising, recurrent epistaxis, gingival bleeding)

      CaseHPOFreeText: Ear bleeding

      CaseNotHPOs: HP:0000967, HP:0000979, HP:0002239, HP:0002239, HP:0000790, HP:0005261, HP:0002248

      (Petechiae, purpura, GI bleeding, intracranial hemorrhage, hematuria, hemarthrosis, hematemesis)

      CaseNotHPOsFreeText: Hemorrage after dental, hemorrhage after trauma, hematoma

      ProteinExpression: N/A

      PlateletAggregation: Defective response to ADP, adrenaline, collagen, arachidonic acid, and normal response to ristocetin

      CasePreviousTesting: Exon PCR was used to amplify a;; coding regions of the ITGA2B and ITGB3 genes. PCR products were purified and Sanger sequenced. Segregation using parental samples was undertaken when available.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1652G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8602986

      gnomAD: MAF in South Asian population is 0.00006536 http://gnomad.broadinstitute.org/variant/17-42457470-C-T

      PreviouslyPublished: PMID: 19172520

    2. A

      Case1: Patient ID A, Male, 6 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A (Parents are consangenous)

      CasePresentingHPOs: HP:0000978, HP:0002239

      (Easy bruising, gastrointestinal bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: HP:0000967, HP:0000979, HP:0004406, HP:0000225, HP:0002239, HP:0000790, HP:0005261

      (Petechiae, purpura, recurrent epistaxis, gingival bleeding, intracranial hemorrhage, hematuria, hemarthrosis)

      CaseNotHPOsFreeText: Hemhorrage after dental, hemhorrage after trauma, ear bleeding, hematoma

      ProteinExpression: N/A

      PlateletAggregation: Defective response to ADP, adrenaline, collagen, arachidonic acid, and normal response to ristocetin

      CasePreviousTesting: Exon PCR was used to amplify a;; coding regions of the ITGA2B and ITGB3 genes. PCR products were purified and Sanger sequenced. Segregation using parental samples was undertaken when available.

      Gene: ITGA2B

      Variant: NM_000419.3:c.435C>A (p.Asn145Lys) and NM_000419.3:c.531T>A (p.Cys177Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805991 and CA290955739

      gnomAD: N/A

      PreviouslyPublished: PMID: 20020534

    1. Patient 2

      Case2: Female, 28 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia type 1

      FamilyInfo: N/A

      ParentalGenotype: Parents were heterozygous for this mutation and did not show bleeding symptoms

      Note: There is parental consanguinity

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Severe haemorrhagia and haematomas associated with prolonged in vivo bleeding time

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis revealed 3.5 % of αIIbβ3 was detected on the platelet surface from patient 2.

      PlateletAggregation: Article states agonist-induced platelet aggregation and binding of exogenous fibrinogen was pathological, too but does not mention specific agonists used or response to ristocetin

      CasePreviousTesting: Molecular genetic analysis was done; however, no other information mentioned. In addition, the global proteome of highlight purified washed platelets was quantified by liquid chromatography-mass spectrometry and targeted MS-methods.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2374del

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940267

      gnomAD: N/A

    1. GT1-III2

      Case#: GT1-III2 male, 11 years old

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: (found in appendix) HP:0001892, HP:0000421, HP:0000225, HP:0000967, HP:0000979, HP:0031364, HP:0006298,

      ExpressionEvidence: Not done

      FamilyInfo: Positive consanguinity, parents heterozygous carriers, 2 affected siblings, one deceased. Pedigree figure 1.

      GenotypingMethod: Sanger DNA sequencing to identify causative mutations in each case

      ClinVar: 1691482

      CAID: CA400021881

      Variant: NM_000212.3:c.422A>G

      GnomAD: Not Found

    1. Supplementary Tables 1 and 2 combined information:

      Case30: GT30, Female, 13

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Not available per supplementary table 1

      ParentalGenotype: Parents are not consanguineous, no other genotype information available

      CasePresentingHPOs: HP:0000978, HP:0000979, HP:0031364, HP:0000421, HP:0000225, HP:0000132

      (Bruising, purpura, ecchymosis, epistaxis, gingival bleeding, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Showed <5% of αIIbβ3 expression measured by flow cytometry

      PlateletAggregation: Platelet aggregation showed no response to ADP and collagen but normal response to ristocetin

      CasePreviousTesting: All exons from ITGA2B and ITGB3 genes were amplified by PCR using intronic primers. DNA sequencing was determined by Sanger sequencing.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2330C>A (p.Ala777Asp) and NM_000419.3:c.2602-3C>G (no protein notation given)

      LegacyVariant: N/A

      ClinVar: 2893 (c.2602-3C>G)

      CAiD: CA399796685 (p.Ala777Asp) and CA10575472 (c.2602-3C>G)

      gnomAD: MAF for East Asian population: 0.00006523 https://gnomad.broadinstitute.org/variant/17-42453087-G-C

    1. GT 02

      Case1: GT02, Female, India, age of onset is 18 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0031364 Gingival bleeding and ecchymosis

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: Menorrhagia HP:0000132

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.2459del (p.Asn820MetfsX5)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940722

      gnomAD: N/A

    2. GT 38

      Case11: GT38, Male, India, age of onset is 8 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.2953C>T (p.Gln985Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399790170

      gnomAD: N/A

    3. GT 26

      Case7: GT26, Female, India, age of onset is 4 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGA2B

      Variant: NM_000419.3:c.2929_2930del (p.Glu979SerfsTer28)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940726

      gnomAD: N/A

    4. GT16

      Case20: GT16, Female, India, age of onset is 11 years old

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Patients were recruited as they presented consecutively from 1996 to 1998 for evaluation of a mucocutaneous bleeding disorder

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: All patients examined had defective ADP, epinephrine, and collagen induced aggregation and normal ristocetin induced aggregation

      CasePreviousTesting: Mutations were detected by the method of single strand conformation polymorphism (SSCP) analysis, followed by nucleotide sequencing and confirmation by restriction fragment length polymorphism (RFLP) assays. The sequences of the primers employed and the reaction conditions for PCR amplification of the exons, adjacent intronic regions, and 50 and 30 untranslated regions of the aIIb and b3 gene

      Gene: ITGB3

      Variant: NM_000212.2:c.428T>G (p.Leu143Trp)

      LegacyVariant: N/A

      ClinVar: 13567

      CAiD: CA123252

      gnomAD: MAF in the Other population is 0.0001629 https://gnomad.broadinstitute.org/variant/17-45361875-T-G

    1. Supplementary Table S1 & S2 Proband and Variant Information:

      Case68: GT72, Female, 56 years old, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0000225, HP:0000132, HP:0002239, HP:0006298

      (Epistaxis, ecchymosis, gingival bleeding, menorrhagia, GI bleeding, prolonged bleeding after dental extraction)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.2951C>A (P.Thr984Lys)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399790180

      gnomAD: N/A

    2. Supplementary Table S1 & S2 Proband and Variant Information:

      Case52: GT52, Male, 24 years old, Argentenian/Brazil

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421

      (Epistaxis)

      CaseHPOFreeText: Hematomas

      (Proband's symptoms decreased during adolescence)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.601G>A (p.Gly201Ser)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399805612

      gnomAD: N/A

    3. Supplementary Table S1 & S2 Proband and Variant Information:

      Case40: GT41a, Female, 15 years old, Chinese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother is proband 41b in this study (See Supplemental Table S1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0004406, HP:0000978

      (Recurrent epistaxis, easy bruising)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.91del (p.Ala31Profs2) and NM_000419.3:c.2915dup (p.Leu973Alafs63)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA913203486 and CA8602531

      gnomAD: MAF in the East Asian population is 0.0001088 http://gnomad.broadinstitute.org/variant/17-42452054-C-CG

    4. Supplementary Table S1 & S2 Proband and Variant Information:

      Case37: GT39a, Female, 23 years old, Swedish/American

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected brother who is proband 39b in this study (See Supplemental Table S1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000421, HP:0006298, HP:0000132

      (Bruising susceptibility, epistaxis, prolonged bleeding after dental extraction, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399801310

      gnomAD: MAF in the Latino population 0.00003983 http://gnomad.broadinstitute.org/variant/17-42456075-G-A

    5. Supplementary Table S1 & S2 Proband and Variant Information:

      Case38: GT39b, Male, 18 years old, Swedish/American

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister who is proband 39a in this study (See Supplemental Table S1)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000978, HP:0000421, HP:0006

      (Bruising susceptibility, epistaxis)

      CaseHPOFreeText: Hematomas after minor trauma

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1882C>T (p.Arg628Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399801310

      gnomAD: MAF in the Latino population 0.00003983 http://gnomad.broadinstitute.org/variant/17-42456075-G-A

    6. Supplementary Table S1 & S2 Proband and Variant Information:

      Case14: GT15, Female, 35, French

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0031364, HP:0000967, HP:0000421, HP:0000225

      (Ecchymosis, petechiae, epistaxis, gingival bleeding)

      CaseHPOFreeText: Bleeding from birth and hematomas from excersize

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% variant expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.2095-19T>A and NM_000419.3:c.2770C>T (p.Gln924Ter)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940312 and CA399792054

      gnomAD: N/A

    7. Supplementary Table S1 & S2 Proband and Variant Information:

      Case28: GT33a, Male, age not specified, USA/Laos

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister who is proband 33b in this article

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0002239

      (Epistaxis, GI bleeding)

      CaseHPOFreeText: Life-threatening bleeding at onset of menses

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry showed <5% expression of αIIbβ3 (See Supplementary Table 1)

      PlateletAggregation: Absent platelet aggregation (See Supplementary Table 1)

      CasePreviousTesting: Sanger sequencing of ITGA2B and ITGB3

      Gene: ITGB3

      Variant: NM_000212.2:c.262C>T (p.Arg88Ter) and NM_000212.2:c.2113del (p.Leu705Cysfs*4)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400020703 and CA8623443

      gnomAD: MAF in the Other population is 0.0001385 http://gnomad.broadinstitute.org/variant/17-45360816-C-T and MAF in the East Asian population is 0.0001087 http://gnomad.broadinstitute.org/variant/17-45380183-TC-T

    1. 8

      Case8: Female, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mild bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Minimal information, not specific enough

      CasePreviousTesting: Sanger sequencing identified disease-causing variants in 18 out of 20 patients (Probands 6 and 14 excluded) with istoantibodies to αIIbβ3. The mutations were evenly distributed between ITGB3 and ITGA2B.

      Gene: ITGB3 and ITGA2B

      Variant: NM_000419.3:c.682C>T (p.Gln228Ter) and NM_000419.3:c.1750C>T (p.Arg584Ter)

      LegacyVariant: N/A

      ClinVar: 2892 (p.Arg584Ter)

      CAiD: CA115834 (p.Arg584Ter) and CA399805421

      gnomAD: MAF in East Asian population 0.0002176 (p.Arg584Ter) http://gnomad.broadinstitute.org/variant/17-42457372-G-A

    1. 4

      Case2: 9 years old, Female, Jewish Iraqi

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0004406

      (Recurrent epistaxis)

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: All patients demonstrated lack of αIIbβ3 surface expression." No specifics are given on the percentage, but test was performed

      PlateletAggregation: Presented with mucocutaneous bleeding, absence of platelet aggregation in response to all physiological agonists in contrast to normal aggregation with ristocetin

      CasePreviousTesting: "Molecular analysis disclosed that patient 2 was homozygous for an out of frame mutation (c.2031–2041 del, exon 13) in ITGB3, and patient 4 was compound heterozygote for the same deletion and a large deletion of 11.2Kb del"

      Gene: ITGB3

      Variant: NM_000212.2:c.2031_2041del (p.Asp677Glufs) and 11.2Kb del (IVS9aluc.2183–6)

      LegacyVariant: N/A

      ClinVar: N/A and 13563

      CAiD: CA915940605 and NA

      gnomAD: N/A

    1. Patient‐III4

      Case1: Male, Israeli-Arab, (age is either 10 or 14)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 1C for pedigree

      ParentalGenotype: See Fig 1C for pedigree

      CasePresentingHPOs: HP:0000421, HP:0031364, HP:0000967

      (Severe epistaxis, ecchymosis, petechiae)

      CaseHPOFreeText: Decline of hemoglobin levels to 5 g dl each time epistaxis occurred

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: N/A

      ProteinExpression: No surface expression of αIIbβ3 was found in patients’ platelets (See Fig 3)

      PlateletAggregation: N/A

      CasePreviousTesting: DNA fragments containing exons and flanking intronic regions of the aIIb and B3 genes were amplified by PCR using primers

      Gene: ITGA2B

      Variant: NM_000419.3:c.97A>G (p.Asn2Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399806951

      gnomAD: N/A

    1. GT10

      Case#: 2 year old, male

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0000967, HP:0000978, HP:0004406, HP:0006298, HP:0001892

      PlateletAgreggation: Defective response to ADP, Adrenaline, Collagen, Arachidonic acid. Normal response to Ristocetin.

      GenotypingMethod: Genomic DNA was extracted from peripheral blood leukocytes for mutational analysis of the αIIb and β3 genes by DNA sequencing

      Allele 1:

      ClinVar: 1330345

      CAID: CA399805484

      Variant: NM_000419.5:c.659A>G

      GnomAD: South Asian at rate of 0.00003266 (1/30614)

      Allele 2:

      ClinVar:

      CAID:

      Variant:

      GnomAD:

      ExpressionEvidence: Flow Cytometry of platelet integrin: 99.9% B3 expression, 16.6% A2B expression

    2. GT13

      Case#: 33 year old, female

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0000967, HP:0000978, HP:0006298

      PlateletAgreggation: Defective response to ADP, Adrenaline, Collagen, Arachidonic acid. Normal response to Ristocetin.

      GenotypingMethod: Genomic DNA was extracted from peripheral blood leukocytes for mutational analysis of the αIIb and β3 genes by DNA sequencing

      ClinVar:

      CAID: CA8603182

      Variant: NM_000419.5:c.1234G>A

      GnomAD: Latino 0.0001453 (5/34414)

      ExpressionEvidence:Flow Cytometry of platelet integrin: 1.3% B3 expression, .3% A2B expression

    3. GT5

      Case#: 19, female

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0000967, HP:0000978, HP:0000225, HP:0006298, HP:0001892

      PlateletAgreggation: Defective response to ADP, Adrenaline, Collagen, Arachidonic acid. Normal response to Ristocetin.

      GenotypingMethod: Genomic DNA was extracted from peripheral blood leukocytes for mutational analysis of the αIIb and β3 genes by DNA sequencing

      Allele 1:

      ClinVar: 1330339

      CAID: CA400024922

      Variant: NM_000212.3:c.856G>A

      GnomAD: Not Found

      Allele 2

      ClinVar: 1330314

      CAID: CA400028591

      Variant: NM_000212.3:c.1288C>T

      GnomAD: Highest in European non-Finnish population 0.000008801 (1/113622)

      ExpressionEvidence: Flow Cytometry of platelet integrin: 10% B3 expression, 86.6% A2B expression

    1. Antibody Removal Therapy Used Successfully at Delivery of a Pregnant Patient with Glanzmann’s Thrombasthenia and Multiple Anti-Platelet Antibodies

      PMID: 1949709

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This mentions a Glanzmann thrombasthenia patient; however, no variants in ITGA2B and/or ITGB3 are mentioned in this patient; therefore, we have insufficient evidence

    1. Case 3

      Case3: Female, 8 years old, Japanese

      DiseaseAssertion: Thrombocytopenia

      FamilyInfo: Information on mother and grandfather available in Table 1(minimal information on other family members)

      ParentalGenotype: Mother: ITGB3 (p.Asp621_Glu660del heterozygous) See Table 1

      CasePresentingHPOs: HP:0000978 (Bruising)

      CaseHPOFreeText: Subaponeurotic hematoma

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Surface expression levels of αIIbβ3 in platelets of patient were decreased to around 65% of normal subjects with increase of CD42b (See Table 1)

      PlateletAggregation: N/A

      CasePreviousTesting: Sequence analysis of DNA revealed the patient's mutation. RT-PCR was also performed. The entire coding sequence of exons and exon-intron boundaries of ITGA2B and ITGB3 and the whole coding regions of ITGA2B and ITGB3 cDNA obtained from platelets were sequenced.

      Gene: ITGB3

      Variant: NM_000212.2:c.2134+1G>A (p.Asp621_Glu660del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400033344

      gnomAD: N/A

    1. Patient LD

      Case1: (Patient LD) Female, 3 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: See Fig 4 for family pedigree

      ParentalGenotype: Father is heterozygous for GC867-G and Mother is heterozygous for T882C (See Fig 4)

      CasePresentingHPOs: HP:0000967, HP:0031364, HP:0000978, HP:0000225

      (Petechiae, ecchymosis, bruising, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Fig 2A shows reduced expression (See Fig2A)

      PlateletAggregation: Platelets did not aggregate in response to ADP, epinephrine, or arachidonic acid and showed only shape change in response to collagen. Platelets did agglutinate with ristocetin.

      CasePreviousTesting: Genomic DNA was prepared from peripheral blood leukocytes and amplified by polymerase chain reaction (PCR) with Taq polymerase by using oligonucleotide primers from intronic flanking sequences of αIIb and β3. All exons of both genes were sequenced at least twice to exclude Taq errors.

      Gene: ITGB3

      Variant: NM_000212.2:c.863T>C (p.Leu288Pro) and NM_000212.2:c.847_848del

      LegacyVariant: (p.Leu262Pro)

      ClinVar: N/A

      CAiD: CA400024958 and CA8623068

      gnomAD: for c.847_848del https://gnomad.broadinstitute.org/variant/17-45364504-AGC-A

    1. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus

      PMID: 12609844

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions 2 major mutations in the calf-1 and calf-2 domains of ITGA2B. There are no specific Glanzmann thromasthenia patients mentioned that harbor these specific variants; therefore, there is insufficient evidence

    1. Case10: Patient PL, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1742C>A (p.Ala581Asp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802112

      gnomAD: N/A

    2. Case15: Patient CE, gender and age are not specified, all of these patients are Caucasian (either Italian or European)

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients presented with a current or past history of bleeding and a bleeding time >15 min. Bleeding symptoms were evaluated by examining available hospital records. Mild bleeders were defined as those who bled only after trauma or surgery or had minor symptoms, such as epistaxis. Moderate/severe bleeders were defined as those with a history of spontaneous or life threatening hemorrhages, such as gastrointestinal bleeding, or who had repeated episodes requiring platelet transfusions

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1

      PlateletAggregation: See Table 1

      CasePreviousTesting: To identify point mutations responsible for GT, we have sequenced all coding regions of Ib and 3 genes and intron/exon boundaries.

      Gene: ITGA2B

      Variant: NM_000419.3:c.2113T>C (p.Cys705Arg)

      LegacyVariant: (p.Arg674Arg)

      ClinVar: N/A

      CAiD: CA8602816

      gnomAD: MAF in the European (non-Finnish) population is 0.000008792 https://gnomad.broadinstitute.org/variant/17-42455140-A-G

    1. GT-55

      Case44: (GT-54) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.2113del (p.Leu705Cysfs*4)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623443

      gnomAD: MAF in East Asian population: 0.0001087 http://gnomad.broadinstitute.org/variant/17-45380183-TC-T

    2. GT-30

      Case25: (GT-30) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT30 is related to GT29

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045 http://gnomad.broadinstitute.org/variant/17-42457471-G-A

    3. GT-44b

      Case34: (GT-44) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT43-GT44 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not available (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1620G>C (p.Gln540His) and NM_000419.3:c.1616T>G (p.Leu539Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802407 and CA399802416

      gnomAD: N/A

    4. GT-73c

      Case54: (GT-73) Gender, age, or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Information not given (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.985A>G (p.Asn329Asp)

      LegacyVariant: N/A

      ClinVar: 323865

      CAiD: CA8623107

      gnomAD: MAF in Other population 0.0005534 http://gnomad.broadinstitute.org/variant/17-45367092-A-G

    5. GT-25

      Case21: (GT-25) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT-26 is related to GT-25 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Mild (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGA2B

      Variant: NM_000419.3:c.1879-2A>G

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290949031

      gnomAD: N/A

    6. GT-32

      Case27: (GT-32) Female, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT31-GT34 are related

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.2113del (p.Leu705Cysfs*4)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA8623443

      gnomAD: MAF in the East Asian population is 0.0001087 http://gnomad.broadinstitute.org/variant/17-45380183-TC-T

    7. GT-21

      Case19: (GT-21) Male, age or ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Proband GT-22 is related to GT-21 see Table 1

      ParentalGenotype: Parents may be included in Table 1; however, not specified so no information

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding severity: Moderate (See Supplementary Table 3)

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry performed and CD41 and CD61 were observed (See Supplementary Table 3)

      PlateletAggregation: Minimal information (See Supplementary Table 3)

      CasePreviousTesting: DNA was extracted from peripheral blood samples from patients and family members, and Sanger sequencing and PCR was performed. Samples were processed for targeted sequencing using the available SHGp heme panel of 393 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.2302-1G>A

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA400034626

      gnomAD: N/A

    1. A gastrointestinal patient

      Case1: Male, 6 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo:

      ParentalGenotype: "No platelet sample from the patient's mother and father were available"

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mild spontaneous mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Assessment of surface expression of αIIBβ3 D217 and αIIBβ3 V217 by flow cytometry was performed. αIIb and β3 were expressed at normal levels.

      Platelet Aggregation: Absence of platelet aggregation in response to agonists such as ADP, epinephrine, or collagen and a normal response to ristocetin

      CasePreviousTesting: Sequencing of αIIb and β3 genes revealed a homozygous missense A>T point mutation in the β3 gene leading to a D217Val substitution.

      Gene: ITGB3

      Variant: NM_000212.2:c.728A>T (p.Asp243Val)

      LegacyVariant: (p.Asp217Val)

      ClinVar: N/A

      CAiD: CA400023604

      gnomAD N/A

    1. PLATELET TRANSFUSION IN A PATIENT AFFECTED BY GLANZMANN'STHROMBASTHENIA WITH ANTIBODIES AGAINST GPIIb-IIIa

      PMID: 9107089

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This mentions a Glanzmann thrombasthenia patient; however, no variants in ITGA2B and/or ITGB3 are mentioned in this patient; therefore, we have insufficient evidence

    1. Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach

      PMID: 29227167

      Gene: ITGA2B and ITGB3

      HGNC: 6138 and 6156

      NoEvidence: This article is about developing a standardized and modular flow cytometric approach, that contributes to clarify impaired platelet function in a rational step by step manner. There is no mention of variants in probands for ITGA2B or ITGB3

    1. 2CabGT-2

      Case2: (Proband CabGT-2), Female, age not specified, European Caucasian

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: N/A

      Platelet Aggregation: N/A

      CasePreviousTesting: Promoter and exon sequences of aIIb and b3 genes were amplified and directly sequence

      Gene: ITGA2B

      Variant: NM_000419.3:c.917dup (p.Arg307GlufsTer22) and NM_000419.3:c.1912dup (p.Cys639MetfsTer22)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA290954352 (p.Arg307GlufsTer22) and CA915940678 (p.Cys639MetfsTer22)

      gnomAD N/A

    1. haematuria21

      Case21: Male, Iraq, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 mentions family history available for the proband, however no specific details about family provided in paper

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGB3

      Variant: NM_000212.2:c.2031_2041del (p.Asp677Glufs)

      LegacyVariant: (p.Asp651Glufs*3)

      ClinVar: N/A

      CAiD: CA915940605

      gnomAD: N/A

    2. 17

      Case17: Female, Arab, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 mentions family history available for the proband, however no specific details about family provided in paper

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225, HP:0031364, HP:0000132, HP:0000132)

      (Epistaxis, gingival bleeding, ecchymosis, menorrhagia, melena)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.409-2_419del

      LegacyVariant: N/A

      ClinVar: 2889

      CAiD: CA10575471

      gnomAD: N/A

    3. 15

      Case15: Male, Arab, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 mentions family history available for the proband, however no specific details about family provided in paper

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421, HP:0000225

      (Epistaxis, gingival bleeding)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: N/A

      CasePreviousTesting: N/A

      Gene: ITGA2B

      Variant: NM_000419.3:c.409-2_419del

      LegacyVariant: N/A

      ClinVar: 2889

      CAiD: CA10575471

      gnomAD: N/A

    1. The patient,

      Case1: (Patient JO) Female, 38 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: Parents shown Fig 6

      CasePresentingHPOs: HP:0000978, HP:000042, HP:0000132

      (Easy bruising, epistaxis, menorrhagia)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      ProteinExpression: Figure 6 shows surface expression

      Platelet Aggregation: Absent aggregation in response to ADP, epinephrine, collagen and thrombin however normal response to ristocetin

      CasePreviousTesting: Total cellular RNA was obtained, and aIIbb3 mRNAs were specifically amplified by reverse transcription PCR (RT-PCR) as previously described (41).

      Gene: ITGA2B

      Variant: NM_000419.3:c.575_576insGGACAA (went over with Shruthi)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA915940650

      gnomAD N/A

    1. GT1

      Case1: GT-1, Female, Catalan, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Affected sister (GT-1) and brother (GT-3)

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000421

      (Epistaxis)

      CaseHPOFreeText: Hemorrhage associated with deciduous tooth loss

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Standard glycoprotein analysis confirmed the absence of αIIbβ3 in their platelets but while western blotting failed to reveal αIIb, residual β3 was at about 10% of usual levels and of normal migration (illustrated for GT1 in supplemental Figure 1).

      PlateletAggregation: Platelets of all 3 patients failed to aggregate in response to a range of physiologic agonists but were agglutinated by ristocetin. Clot retraction was also defective.

      CasePreviousTesting: Screened ITGA2B and ITGB3 genes of all three probands. Direct sequencing of all coding regions and splice sites of ITGA2B (30 exons) showed mutation.

      Gene: ITGA2B

      Variant: NM_000419.3:c.131G>T and NM_000419.3:c.1440-13_1440-1del

      LegacyVariant: (p.Gly13Val)

      ClinVar: N/A

      CAiD: CA399806881 and CA913184940

      gnomAD: N/A

    1. M/14

      Case6: Male, 14 years old, Tamil Nadu India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0006298, HP:0000967

      (Gingival bleeding, prolonged bleeding after tooth extraction, petechiae)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGA2B

      Variant: NM_000419.3:c.1651C>T (p.Arg551Trp)

      LegacyVariant: (p.Arg520Trp)

      ClinVar: N/A

      CAiD: CA399802348

      gnomAD: MAF in the East Asian population is 0.00005045https://gnomad.broadinstitute.org/variant/17-42457471-G-A

    2. F/12

      Case10: Female, 12 years old, Tamil Nadu India

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: HP:0000225, HP:0006298

      (Gingival bleeding, prolonged bleeding after dental extraction)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: See Table 1 for values

      PlateletAggregation: See Table 1 for values

      CasePreviousTesting: PCR amplification of ITAG2B and ITGB3

      Gene: ITGB3

      Variant: 330_336TCCCCAGdel is not showing up in CAR noting it as Unregistered

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: Unregistered

      gnomAD: N/A

    1. Glanzmann's Thrombastenia: The Role of Tranexamic Acid in Oral Surgery

      PMID: 30254767

      Gene: ITGA2B and/or ITGB3 (Proband diagnosed with Gt therefore these genes may be involved here)

      HGNC: 6138 and 6156

      InsufficientEvidence: Proband with Glanzmann Thrombasthenia described here however no mention of variants therefore insufficient evidence

    1. BlockingPlateletAggregationInhibitsThromboxaneA2FormationbyLowDoseAgonistsButDoesNotInhibitPhosphotylationandActivationofCytosolicPhospholipaseA2.

      PMID: 9361365

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156, respectively

      NoEvidence: This article does not mention Glanzmann thrombasthenia patients/probands with variants in ITGA2B and/or ITGB3. In this study, they made use of Ro 44-9883 as a potent non-peptide GPIIb/IIIa antagonist to address the relationship of platelet aggregation to PLA2 activation, TxA2 formation, and granule secretion.

    1. 3/M

      Case#: Patient ID 7, Male 3 years old. North Indian

      Disease: Glazmann's Thrombasthenia

      CasePresentingHPOs: HP:0003540, HP:0000421, HP:0031364

      Impaired platelet aggregation, Epistaxis, Ecchymosis

      PlateletAgreggation: LTA with ADP, Epi, Coll, AA, and Ristocetin: Impaired with all except Ristocetin

      FamilyInfo: Brother affected confirmed GT.

      GenotypingMethod: Next generation sequencing. Sanger sequencing used to confirm pathogenic variants

      ClinVar: 1691487

      CAID: CA400029054

      Variant: NM_000212.3:c.1388G>C

      GnomAD: NA

      ExpressionEvidence:Flow Cytometry for platelet expression of GPIIb/IIIa in CD41a .5% and CD61 1.7%.

    1. Mechanistic Insights from a Refined Three-dimensionalModel of IntegrinIIb3*

      PMID: 15056669

      Gene: ITGA2B and ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions Glanzmann thrombasthenia variants; however, no patients with GT are mentioned with these variants therefore we have insufficient evidence

    1. Critical Residues of IntegrinaIIb Subunit for Binding ofaIIbb3(Glycoprotein IIb-IIIa) to Fibrinogen and Ligand-mimeticAntibodies (PAC-1, OP-G2, and LJ-CP3)*

      PMID: 8702512

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions variants in ITGA2B and/or ITGB3; however, there are no Glanzmann thrombasthenia case reports mentioned in this article therefore we have insufficient evidence

    1. Patient TK

      Case1: (Patient TK) Male, 5 years old, Japanese

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: The (p.His280Pro) mutation was inherited from his mother and the (p.Gly579Ser) mutation was inherited from his father

      CasePresentingHPOs: N/A

      CaseHPOFreeText: All patients (3 in this study) had suffered from a bleeding diathesis since early childhood

      CaseNotHPOs: NA

      ProteinExpression: The surface expression of the alphaIIbbeta complex on the patients' platelets was quantitated by flow cytometry. The level of antigen expression for TK was 19.9%

      Platelet Aggregation: Absent platelet aggregation in response to ADP, collagen, and epinephrine, but normal platelet agglutination in response to ristocetin

      CasePreviousTesting: The nucleotide sequences of the aIIb and b3 coding regions were determined by direct sequencing of RT-PCR products from platelet RNA

      Gene: ITGB3

      Variant: NM_000212.2:c.917A>C (p.His206Pro) and NM_000212.2:c.1813G>A (p.Gly605Ser) (See Table 1 to see zygosity statement, "double heterozygote for both variants")

      LegacyVariant: (p.His280Pro) and (p.Gly579Ser)

      ClinVar: N/A

      CAiD: CA291224999 and CA291227621

      gnomAD MAF in the East Asian population for (p.His206Pro) is 0.00005437 https://gnomad.broadinstitute.org/variant/17-45364575-A-C and MAF in East Asian population for (p.Gly605Ser) is 0.00005437 https://gnomad.broadinstitute.org/variant/17-45376796-G-A

    1. VI:5

      Case#: Male, Saudi

      Disease: Glazmann's Thrombasthenia, 9 affected family members including proband. Figure 1.

      Family: Large six-generation consanguineous

      CasePresentingHPOs: HP:0000978, HP:0001892

      Bruising susceptibility, Abnormal bleeding

      PlateletAgreggation: No platelet aggregation to adenosine-di-phosphate, epinephrine, collagen, and arachidonic acid

      GenotypingMethod: Wide Exome sequencing identified pathogenic mutation. Sanger sequencing validated segregation of mutation in family.

      ClinVar: 953051

      CAID:CA8623443

      Variant: NM_000212.3:c.2113del

      GnomAD: East Asian at rate of (0.0001087) 2/18394

      ExpressionEvidence: Affected individuals were found negative for CD41 and CD61 surface antigens; however, CD42a and CD42b antigens were found positive. Used to test presence and absence of integrin αIIbβ3 complex

    1. 9-year-old boy

      Case1: Male, 9 years old,

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: One brother, with no signs of bleeding diathesis

      ParentalGenotype: Father is heterozygous for the c.2268C>T mutation and the mother is compound heterozygous with the c.2268C>T variant and c.2330C>T variant

      CasePresentingHPOs: HP:0000421 Epistaxis

      CaseHPOFreeText: Submucosal bleeding, hematomas, excessive achilles tendon bleeding

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: The patient's αIIbβ3 receptor count was estimated approximately 50% of that measured in a healthy age-matched control by quantitative flow cytometry

      PlateletAggregation: Complete absense of platelet aggregation in response to ADP, arachidonic acid, epinephrine, collagen

      CasePreviousTesting: Direct sequencing of the patients αIIb and β3 genes was perforemed

      Gene: ITGB3

      Variant: NM_000212.2:c.2248C>T (p.Arg750Ter)

      LegacyVariant: (p.Arg724Ter)

      ClinVar: 13564

      CAiD: CA123246 (p.Arg750Ter)

      gnomAD: N/A

    1. Thalidomide for the Treatment of Gastrointestinal Bleeding Due to Angiodysplasia in a Patient with Glanzmann’s Thrombasthenia

      PMID: 28670433

      Gene: ITGA2B and ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article describes a proband with Glanzmann thrombasthenia; however, there is no mention of variants in ITGA2B and ITGB3 in this proband.

    1. GT1

      Case1: (GT1), Male, 60 years old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding defects

      CaseNotHPOs: N/A

      ProteinExpression: <5% surface expression levels of αIIbβ3

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGB3

      Variant: NM_000212.2:c.1031A>C (p.Tyr344Ser)

      LegacyVariant: (p.Tyr318Ser) (The paper gives legacy and current nomenclature)

      ClinVar: N/A

      CAiD: CA400025814

      gnomAD N/A

    2. M5

      Case13: (M5) Male, 9 years old, French Gypsy

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Mucocutaneous bleeding

      CaseNotHPOs: N/A

      ProteinExpression: Failed to express alphaIIbbeta3 on the surface of their platelets

      Platelet Aggregation: Absent platelet aggregation to all agonists (no mention for which agonists or response to ristocetin)

      CasePreviousTesting: All the information we are given is "mutation screening of the ITGA2B and ITGB3 genes" the method for sequencing etc. was not stated

      Gene: ITGA2B

      Variant: NM_000419.3:c.1544+1G>A

      LegacyVariant: N/A

      ClinVar: 2895

      CAiD: CA10575473

      gnomAD N/A

    1. Glanzmann's Thrombasthenia Diagnosed following Knee Arthroscopy

      PMID: 26000186

      Gene: Patient could have variation in ITGA2B or ITGB3, article does not specify; however, patient has GT so it is implied one of the two genes is involved

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions a proband who was diagnosed with Glanzmann thrombasthenia; however, there is no mention of variants in ITGA2B or ITGB3 in this patient; therefore, we have insufficient evidence

    1. Supplemental Table S1:

      Case2: Female, India, age not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: N/A

      ParentalGenotype: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      PlateletAggregation: Absent platelet aggregation (all the information that is provided in Supp. Table S1)

      CasePreviousTesting: Sanger sequencing of exons, splice sites and untranslated regions of the ITGA2B and ITGB3 genes was performed

      Gene: ITGA2B

      Variant: NM_000419.3:c.1520C>G (p.Pro507Arg)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA399802643

      gnomAD: N/A

      PreviouslyPublished: PMID: 16463284

    1. The patient

      Case1: Female, 21 years old, ethnicity not specified

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Blood samples collected from brother, no other information provided

      ParentalGenotype: Father heterozygous: NM_000419.3:c.258G>C and mother heterozygous: NM_000419.3:c.2334A>C

      CasePresentingHPOs: HP:0000421, HP:0000979

      (Epistaxis, purpura)

      CaseHPOFreeText: N/A

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: Flow cytometry analysis and western blot analysis showed a remarkable reduction in aIIb b3 and aIIb, and a moderate reduction in b3 in the platelets of the patient (data not shown)

      PlteletAggregation: N/A

      CasePreviousTesting: Nucleotide sequences of aIIb cDNA and b3 cDNA amplified by reverse transcription polymerase chain reaction (RT-PCR) were analyzed

      Gene: ITGA2B

      Variant: NM_000419.3:c.258G>C (p.Leu86Pro) and NM_000419.3:c.2334A>C

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA500624524 and CA399796662

      gnomAD: N/A

    1. Total Extraction as a Treatment for Anaemia in a Patient of Glanzmann’s Thrombasthenia with Chronic Gingival Bleed: Case Report

      PMID: 26894187

      Gene: ITGA2B and/or ITGB3 (Article does not explicitly state these genes; however, patient has Glanzmann thrombasthenia so these two genes are implied)

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions a case report of an 18 year old male patient with Glanzmann thromasthenia; however, there are no variants in ITGA2B or ITGB3 that are mentioned here

    1. GT3

      Disease: Glazmann's Thrombasthenia

      Case: 19 year old female French Gypsy

      CasePresentingHPOs: HP:0001975

      (Decreased platelet glycoprotein IIb-IIIa)

      GenotypingMethod:Genotyping analysis of the HPA-1 system by high resolution melting analysis (methods not provided, cited article I don't have access too)

      ClinVar: 2895

      CAID: CA10575473

      Variant: NM_000419.5:c.1544+1G>A

      GnomAD: Not found

      ExpressionEvidence: Failed to express αIIbβ3 integrin on their platelet surface (methods not provided cited article no access too)

    2. GT2

      Disease: Glazmann's Thrombasthenia

      Case: 8 year old female French Gypsy

      CasePresentingHPOs: HP:0001975

      (Decreased platelet glycoprotein IIb-IIIa)

      GenotypingMethod:Genotyping analysis of the HPA-1 system by high resolution melting analysis (methods not provided, cited article I don't have access too)

      ClinVar: 2895

      CAID: CA10575473

      Variant: NM_000419.5:c.1544+1G>A

      GnomAD: Not found

      ExpressionEvidence: Failed to express αIIbβ3 integrin on their platelet surface (methods not provided cited article no access too)

    1. A systematic review of the management and outcomes ofpregnancy in Glanzmann thrombasthenia

      PMID: 21457404

      Genes: ITGA2B and ITGB3

      HGNC: 6138 and 6156

      Insufficient Evidence: This article reports the results of a systematic review of management and outcome data contained within all published descriptions of pregnancy in GT. Probands with GT are mentioned; however, no variants are mentioned.

    1. INHERITEDDEFECTS OFPLATELETFUNCTION

      PMID: 11844132

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions variants in ITGA2B and ITGB3; however, there are no specific Glanzmann thrombasthenia patients with the mentioned variants; therefore, there is insufficient evidence

    1. Carrier Detection in Glanzmann ThrombastheniaComparison of Flow Cytometry and Western Blot With Respect to DNA Mutation

      PMID: 18550477

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions probands with GT; however, the probands are clumped together, and variants are not specifically tied to probands

    1. Concomitant occurrence of mucopolysaccharidosis IIIB and Glanzmann's thrombasthenia. Further

      PMID: 1606713

      Gene: ITGA2B and/or ITGB3

      HGNC: 6138 and 6156

      InsufficientEvidence: This article mentions a Glanzmann thrombasthenia patient and family members of the patient; however, there is no mention of variants in ITGA2B and/or ITGB3; therefore, there is insufficient evidence

    1. 2

      Case2: No assertion made on age, gender or ethnicity

      DiseaseAssertion: Glanzmann thrombasthenia

      FamilyInfo: Table 1 states family history is available.

      ParentalGenotype: The identified variants were heterozygote in parents and were not present as homozygote in their healthy members of the family as expected in cases where mutations are deleterious.

      CasePresentingHPOs: N/A

      CaseHPOFreeText: Bleeding time is greater than 20 minutes and prolonged clotting time

      CaseNotHPOs: N/A

      CaseNotHPOsFreeText: N/A

      ProteinExpression: N/A

      CasePreviousTesting: Genetic study of patient was conducted using direct sequencing of entire coding and exon-intron boundaries of the ITGA2B and ITGB3 genes.

      Gene: ITGB3

      Variant: NM_000212.2:c.1658_1660del (p.Ser553del)

      LegacyVariant: N/A

      ClinVar: N/A

      CAiD: CA626684826 (p.Ser553del)

      gnomAD: MAF in Latino population: 0.0001158 https://gnomad.broadinstitute.org/variant/17-45369899-TCTC-T